Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma

Arsenic trioxide (ATO) induces remission in 85% of adults with refractory acute promyelocytic leukemia (APL). We conducted a phase 1 trial of ATO in children (median age 13 y, range, 2-19) with refractory leukemia. ATO was administered intravenously over 2 hours, 5 d/wk for 20 doses/cycle. Patients...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Fox, Elizabeth, Razzouk, Bassem I., Widemann, Brigitte C., Xiao, Shaun, O'Brien, Michelle, Goodspeed, Wendy, Reaman, Gregory H., Blaney, Susan M., Murgo, Anthony J., Balis, Frank M., Adamson, Peter C.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2008
Konular:
Clinical Trials and Observations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2200837/
https://ncbi.nlm.nih.gov/pubmed/17959855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-08-107839
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller